Clinical trials: Mental Function
Sleep Initiation and Maintenance Disorders, Insomnia
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with…
- Trial name
- NCT00354809
- Testing
- GW679769
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Insomnia, Arthritis, Rheumatoid
Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
To demonstrate subjective sleep efficacy of eszopiclone 3 mg in subjects with insomnia related to rheumatoid arthritis (RA).
- Trial name
- NCT00367965
- Testing
- Eszopiclone
- Where
- 38 sites in United States
- Volunteers
- 153 people
- Sponsor
- Sumitomo Pharma America, Inc.
Autism Spectrum Disorder
Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)
This study will test whether a noninvasive brain stimulation treatment called Functional Neurogenesis Stimulation (using the NeuroCytontron device) can safely improve core symptoms of Autism Spectrum Disorder (ASD) in children.
- Trial name
- NCT07276555
- Testing
- Functional Neurogenesis Stimulation Therapy
- Where
- 2 sites in United States, Mexico
- Volunteers
- 256 people
- Sponsor
- Neurocytonix, Inc.
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Alzheimer's Disease
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
This is a single centre, 2 part study in older subjects. Part 1 (Pharmacokinetic [PK] Assessment) is a double blind, randomized, placebo-controlled 4-period crossover study investigating the PK profile of four different doses of…
- Trial name
- NCT01702480
- Testing
- GSK2981710
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- GlaxoSmithKline
Cognitive Function
Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes
Radicle Clarity DSTTM: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on mental clarity and related health outcomes.
- Trial name
- NCT07342192
- Testing
- RS Clarity Active Product
- Where
- United States
- Volunteers
- 990 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Menopause, Sleep Disturbance
Radicle Revive 24: A Study of Health and Wellness Products on Menopausal Health and Related Health Outcomes
A randomized, double-blind, placebo-controlled, direct-to-consumer trial assessing the impact of health and wellness products on hormonal health and associated health outcomes in women with menopausal health issues
- Conditions
- Menopause, Sleep Disturbance, Anxiety, Depression
- Trial name
- NCT06749288
- Testing
- Radicle Revive Active Study Product 4.1 Usage
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Autism Spectrum Disorder
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female subjects with moderate hepatic impairment compared…
- Trial name
- NCT03912350
- Testing
- Balovaptan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Insomnia
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NBI-34060 is an investigational (research) medication being studied in people with insomnia. The current study is designed to evaluate how people, who experience a nighttime awakening with difficulty returning to sleep, feel…
- Trial name
- NCT00525941
- Testing
- NBI-34060
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Efficacy Study on Cognitive Functions in Schizophrenic Patients
Primary objectives To compare neurocognitive effects of amisulpride with those of risperidone in patients with chronic schizophrenia, as assessed by the general cognitive index, a measure of overall cognitive functioning in…
- Trial name
- AMIMIND (NCT00761670)
- Testing
- amisulpride and risperidone
- Where
- Hungary
- Volunteers
- 37 people
- Sponsor
- Sanofi
Erectile Dysfunction
A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction
To find out more information on how treating impotence with vardenafil in comparison to placebo affects the quality of life (QoL) of men and their partners.
- Trial name
- NCT00661700
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 23 sites in Ireland, United Kingdom
- Volunteers
- 611 people
- Sponsor
- Bayer
Asperger Syndrome, High Functioning Autism
Portable Visual Guidance System Phase II
Abstract: In Phase I, we designed and tested a Portable Visual Guidance System (PVGS), which combines a PDA - for user guidance - and an Internet website - for linking the user to an educational support team.
- Trial name
- PVGS-II (NCT00848874)
- Testing
- PVGS
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Minna Levine, PhD
Mental Health Wellness 1, Work Related Stress
Mental Balance Study
The proposed design is a randomised, double-blind, controlled, crossover intervention assessing the effects of an active intervention, containing Scutellaria baicalensis and Crataegus, versus placebo, on stress, cognition, sleep…
- Trial name
- NCT05757050
- Testing
- Re-Focus "Verum" Tablets
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- A. Vogel AG
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Alzheimer Disease
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living…
- Trial name
- NCT07571161
- Testing
- Donanemab
- Where
- 30 sites in China
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company